ID   NZM035
AC   CVCL_S427
SY   NZM35
DR   cancercelllines; CVCL_S427
DR   Cosmic; 2007668
DR   Wikidata; Q54931567
RX   PubMed=23658559;
RX   PubMed=32567790;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
ST   Source(s): PubMed=32567790
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 11,12
ST   D16S539: 9,10
ST   D18S51: 17
ST   D19S433: 13,15.2
ST   D21S11: 29,32.2
ST   D2S1338: 17,21
ST   D3S1358: 14,15
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 10,12
ST   FGA: 22,26
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 19-12-24; Version: 11
//
RX   PubMed=23658559; DOI=10.3389/fgene.2013.00066; PMCID=PMC3647113;
RA   Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S.,
RA   Finlay G.J., Shelling A.N., Baguley B.C.;
RT   "Comparison of responses of human melanoma cell lines to MEK and BRAF
RT   inhibitors.";
RL   Front. Genet. 4:66.1-66.6(2013).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//